Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

a milestone payment from Johnson &

Johnson Pharmaceutical Research and Development, LLC (J&JPRD) triggered

by J&JPRD's selection of a compound targeting the Cathepsin S enzyme as

a development candidate emerging from a collaboration with Sunesis.

-- Lesley A. Stolz, Ph.D., joined Sunesis in November 2007 as Vice

President, Corporate and Business Development.

Financial Highlights

-- Revenue totaled $2.0 million and $9.7 million, respectively, for the

three months and year ended December 31, 2007, compared to $2.0 million

and $13.7 million for the three months and year ended December 31,

2006. The decrease in revenue year-over-year was primarily due to

lower milestone payments from Merck & Co., Inc. in 2007 compared to

2006.

-- Research and development (R&D) expense was $8.3 million for the fourth

quarter of 2007, compared to $8.5 million for the same period in 2006.

R&D expense for the year ended December 31, 2007 totaled $36.1 million,

compared to $35.6 million in 2006. The year-over-year increase in R&D

expense was primarily due to increased clinical trial activity for SNS-

595 and preclinical program costs, partially offset by lower headcount

and lower R&D expense associated with SNS-032 and SNS-314 due to

reduced research activities in these programs.

-- General and administrative (G&A) expense for the fourth quarter of 2007

was $2.8 million, compared to $3.4 million for the fourth quarter of

2006. For the year ended December 31, 2007, G&A expense was $13.6

million, compared to $12.3 million in 2006. The quarter-over-quarter

decrease primarily resulted from lower professional services expense in

2007 compared to 2006. The year-over-year increase in G&A expense was

primarily due to increased non-cash stock-based compensation expense,
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)... ALTO, Calif. , Jan. 22. 2015  Varian Medical Systems ... and software, has been honored for its commitment to sustainability ... sustainable companies. Varian is the highest ranked healthcare equipment company ... announced today during the World Economic Forum at ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, ... in critical areas, announced the closing of an underwritten public ... purchase up to an aggregate 3,500,000 shares of common stock, ... per warrant.  The warrants have a per share exercise price ...
(Date:12/24/2014)... 2014 Earlier this year in a June ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... property of adult tissue stem cells. His title “Asymmetric ... for the Future,” embodied the essence of his message to ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... 10 ,Anesiva, Inc. (Nasdaq: ANSV ) today ... Drug Application (sNDA) with the U.S. Food and ... to treat the pain,associated with peripheral IV insertions ... powder intradermal,injection system is already approved by the ...
... based on data previously reported, communicated in late 2007 ... ... 7 Ortho Biotech Products, L.P.,today modified prescribing information for PROCRIT(R) (Epoetin ... for all drugs within the erythropoiesis-stimulating agent,(ESA) class., Modifications to the ...
... West Pharmaceutical,Services, Inc. (NYSE: WST ) today announced ... Day event on Thursday, March 13, 2008 from 8:30am,to ... the Grand Hyatt,Hotel in New York, New York., ... look at,the Company,s global operations, business segments, supply chain ...
Cached Biology Technology:Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults 2Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults 3Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 5Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 6Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 7West to Host Investor Day 2
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Global Wearable Technologies Market ... Share, Overview, Trends and Forecast 2014-2020" report ... Technologies are smart devices that can be worn ...
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces it ... Robbins for the 2015 International CES debut of the ... will be at the NXT-ID booth January 6th and ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... and sea slug expert at the California Academy of ... by the Encyclopedia of Life (EOL). These early-career ... their biodiversity research with colleagues and the general public. ... international collaboration that aims to provide freely accessible information ...
... , MOUNTAIN VIEW, CA January 11, 2011 23andMe ... to be the 10 most interesting and significant genetic findings ... the role of genetics in personal health and human development. ... at a phenomenal rate," stated Anne Wojcicki, co-founder and CEO ...
... cafeteria lines to their menu of tools to help ... U.S. Department of Agriculture recently awarded $40,000 from the ... Conklin, associate professor, hospitality management; and Lisa Bailey-Davis, senior ... project will use economic concepts to study the effect ...
Cached Biology News:Encyclopedia of Life names Dr. Rebecca Johnson a 2011 Rubenstein Fellow 2Encyclopedia of Life names Dr. Rebecca Johnson a 2011 Rubenstein Fellow 323andMe presents top 10 most interesting genetic findings of 2010 223andMe presents top 10 most interesting genetic findings of 2010 323andMe presents top 10 most interesting genetic findings of 2010 423andMe presents top 10 most interesting genetic findings of 2010 523andMe presents top 10 most interesting genetic findings of 2010 623andMe presents top 10 most interesting genetic findings of 2010 723andMe presents top 10 most interesting genetic findings of 2010 823andMe presents top 10 most interesting genetic findings of 2010 923andMe presents top 10 most interesting genetic findings of 2010 1023andMe presents top 10 most interesting genetic findings of 2010 1123andMe presents top 10 most interesting genetic findings of 2010 1223andMe presents top 10 most interesting genetic findings of 2010 1323andMe presents top 10 most interesting genetic findings of 2010 1423andMe presents top 10 most interesting genetic findings of 2010 1523andMe presents top 10 most interesting genetic findings of 2010 1623andMe presents top 10 most interesting genetic findings of 2010 1723andMe presents top 10 most interesting genetic findings of 2010 18Quick school cafeteria lines could lead to healthier food choices 2
Incomplete Adjuvant...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: